Compare Stocks

Date Range: 

 Passage BioAligos TherapeuticsAdverum BiotechnologiesCellectisAerie Pharmaceuticals
SymbolNASDAQ:PASGNASDAQ:ALGSNASDAQ:ADVMNASDAQ:CLLSNASDAQ:AERI
Price Information
Current Price$17.29$27.13$3.78$16.30$17.51
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score1.81.51.61.31.7
Analysis Score3.43.54.23.43.3
Community Score3.33.32.32.93.0
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.01.7
Earnings & Valuation Score0.60.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price Target$27.32$35.75$14.88$34.67$24.13
% Upside from Price Target57.98% upside31.77% upside293.52% upside112.68% upside37.78% upside
Trade Information
Market Cap$933.26 million$1.03 billion$370.16 million$740.92 million$821.04 million
BetaN/AN/A1.722.590.79
Average Volume412,31568,6161,735,425393,299648,906
Sales & Book Value
Annual RevenueN/AN/A$250,000.00$22.99 million$69.89 million
Price / SalesN/AN/A1,480.6632.2311.75
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/A$2.71 per share$8.37 per share$3.60 per share
Price / BookN/AN/A1.391.954.86
Profitability
Net IncomeN/AN/A$-64,490,000.00$-102,090,000.00$-199,580,000.00
EPSN/AN/A($1.01)($2.41)($3.40)
Trailing P/E Ratio0.000.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-110.52%-231.05%
Return on Equity (ROE)N/AN/A-32.23%-23.56%-135.57%
Return on Assets (ROA)N/AN/A-28.02%-16.69%-37.23%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.10%3.41%
Current Ratio18.30%N/A28.53%6.11%3.33%
Quick Ratio18.30%N/A28.53%6.00%3.10%
Ownership Information
Institutional Ownership Percentage67.59%N/A97.41%33.30%99.89%
Insider Ownership PercentageN/AN/A12.40%16.41%9.72%
Miscellaneous
Employees7474167272365
Shares Outstanding53.98 million38.14 million97.93 million45.46 million46.89 million
Next Earnings Date8/12/2021 (Estimated)5/10/2021 (Confirmed)8/9/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Aeries (AERI) Q1 Loss Wider Than Expected, Revenues MissAerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
finance.yahoo.com - May 6 at 4:41 PM
Aerie Pharmaceuticals (NASDAQ:AERI) Releases  Earnings Results, Misses Estimates By $0.03 EPSAerie Pharmaceuticals (NASDAQ:AERI) Releases Earnings Results, Misses Estimates By $0.03 EPS
americanbankingnews.com - May 6 at 3:11 PM
Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare ConferenceAerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference
finance.yahoo.com - May 6 at 11:41 AM
Aerie: Q1 Earnings SnapshotAerie: Q1 Earnings Snapshot
apnews.com - May 5 at 6:58 PM
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue EstimatesAerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
msn.com - May 5 at 6:58 PM
Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateAerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 5 at 6:58 PM
Is a Surprise Coming for Aerie (AERI) This Earnings Season?Is a Surprise Coming for Aerie (AERI) This Earnings Season?
finance.yahoo.com - May 4 at 2:31 PM
 Analysts Expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Will Post Quarterly Sales of $23.35 Million Analysts Expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Will Post Quarterly Sales of $23.35 Million
americanbankingnews.com - May 4 at 1:02 AM
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to Post Earnings of -$0.69 Per ShareAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to Post Earnings of -$0.69 Per Share
americanbankingnews.com - May 3 at 12:18 AM
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Given Average Recommendation of "Buy" by BrokeragesAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 30 at 2:54 PM
Aerie Pharmaceuticals (NASDAQ:AERI) Coverage Initiated at Needham & Company LLCAerie Pharmaceuticals (NASDAQ:AERI) Coverage Initiated at Needham & Company LLC
americanbankingnews.com - April 30 at 2:10 PM
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of PatientAerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patient
us.acrofan.com - April 29 at 9:46 AM
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye DiseaseAerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
finance.yahoo.com - April 29 at 9:46 AM
Aerie Pharmaceuticals (AERI) Set to Announce Quarterly Earnings on WednesdayAerie Pharmaceuticals (AERI) Set to Announce Quarterly Earnings on Wednesday
americanbankingnews.com - April 29 at 8:16 AM
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - April 28 at 1:59 PM
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingAerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
finance.yahoo.com - April 28 at 8:59 AM
Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
finance.yahoo.com - April 28 at 8:59 AM
Ophthalmic Drugs Market: Industry Report, Trends, Share and Forecast To 2027Ophthalmic Drugs Market: Industry Report, Trends, Share and Forecast To 2027
marketwatch.com - April 27 at 1:07 PM
Aerie Pharmaceuticals (NASDAQ:AERI) Shares Gap Down to $18.04Aerie Pharmaceuticals (NASDAQ:AERI) Shares Gap Down to $18.04
americanbankingnews.com - April 27 at 12:04 PM
Contrasting Applied Genetic Technologies (NASDAQ:AGTC) and Aerie Pharmaceuticals (NASDAQ:AERI)Contrasting Applied Genetic Technologies (NASDAQ:AGTC) and Aerie Pharmaceuticals (NASDAQ:AERI)
americanbankingnews.com - April 24 at 10:19 AM
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): What It’s Worth And What To Do About ItAerie Pharmaceuticals, Inc. (NASDAQ:AERI): What It’s Worth And What To Do About It
marketingsentinel.com - April 24 at 7:45 AM
Aerie Pharmaceuticals (NASDAQ:AERI) Earns Buy Rating from Analysts at Needham & Company LLCAerie Pharmaceuticals (NASDAQ:AERI) Earns Buy Rating from Analysts at Needham & Company LLC
americanbankingnews.com - April 23 at 1:04 PM
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great BritainAerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
finance.yahoo.com - April 19 at 9:41 AM
$23.31 Million in Sales Expected for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) This Quarter$23.31 Million in Sales Expected for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) This Quarter
americanbankingnews.com - April 17 at 1:08 AM
 Analysts Expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Will Post Earnings of -$0.69 Per Share Analysts Expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Will Post Earnings of -$0.69 Per Share
americanbankingnews.com - April 16 at 12:18 AM
DateCompanyBrokerageAction
3/15/2021Passage BioChardan CapitalBoost Price Target
3/10/2021Passage BioThe Goldman Sachs GroupUpgrade
2/4/2021Passage BioGuggenheimInitiated Coverage
1/25/2021Passage BioWedbushInitiated Coverage
1/4/2021Passage BioJPMorgan Chase & Co.Upgrade
12/11/2020Passage BioSmith Barney CitigroupInitiated Coverage
12/11/2020Passage BioCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/24/2020Passage BioCowenInitiated Coverage
4/1/2021Aligos TherapeuticsJefferies Financial GroupReiterated Rating
3/24/2021Aligos TherapeuticsPiper SandlerBoost Price Target
11/10/2020Aligos TherapeuticsCantor FitzgeraldInitiated Coverage
5/5/2021Adverum BiotechnologiesSVB LeerinkLower Price Target
5/5/2021Adverum BiotechnologiesRoyal Bank of CanadaReiterated Rating
5/5/2021Adverum BiotechnologiesTruist SecuritiesReiterated Rating
4/29/2021Adverum BiotechnologiesLifesci CapitalDowngrade
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
4/29/2021CellectisRobert W. BairdReiterated Rating
3/8/2021CellectisWilliam BlairReiterated Rating
8/6/2020CellectisOppenheimerReiterated Rating
2/19/2020CellectisBTIG ResearchBoost Price Target
12/16/2019CellectisNomura SecuritiesReiterated Rating
3/13/2019CellectisBarclaysReiterated Rating
4/30/2021Aerie PharmaceuticalsNeedham & Company LLCInitiated Coverage
3/1/2021Aerie PharmaceuticalsHC WainwrightReiterated Rating
12/28/2020Aerie PharmaceuticalsMizuhoReiterated Rating
10/19/2020Aerie PharmaceuticalsBank of AmericaDowngrade
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.